Promomed Group added a new drug for blood cancer to its anticancer portfolio

Promomed Group received approval for lenalidomide for the treatment of multiple myeloma. It became the fourth drug in the company's anticancer portfolio.

Multiple myeloma is one of the most common diseases in hematology, the second most common malignant hematological disease. Until recently, it was considered a disease of the elderly people, but over the past few years, the disease has been increasingly detected in people aged 45-50 years. More than 4,000 thousand cases are diagnosed every year in Russia alone.

The drug contains the active substance lenalidomide, which affects the body's immune system and has a direct effect on tumor cells by suppressing their growth.

The formation of a portfolio of medicines aimed at the treatment of socially significant diseases, including cancer, is one of the most important tasks for the Promomed Group as part of a strategy to solve global medical problems, save lives and significantly improve the health of patients. When introducing new drugs to the market, including generics, the company offers patients effective and safe medicines due to the high quality of pharmaceutical substances, the processability in manufacturing, and the highest quality control standards.

Lenalidomide-Promomed will be available in capsules with a dosage from 2.5 mg to 25 mg, which corresponds to standard dosage regimens.

Like most medicines produced by Promomed Group, this drug is included in the list of vital and essential drugs.